Flash Finance

Clinitech Laboratory Ltd544220Corporate

Latest results: Mar 2026 6 quarters of data
Consolidated Standalone
—
MCap —
Live price not available
Clinitech Laboratory Ltd — Stock analysis & AI research Clinitech Laboratory Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹4 Cr
Sales · Mar 2026
+5.5% YoY
₹0 Cr
Operating Profit · Mar 2026
+60.7% YoY
10.3%
OPM % · Mar 2026
+53.7% YoY
₹0 Cr
Net Profit · Mar 2026
-29.4% YoY
₹0.53
EPS · Mar 2026
-28.4% YoY

📝 Clinitech Laboratory Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Clinitech Laboratory Ltd reported revenue of ₹4 crore for the quarter ended March 2026 (Q4 FY26), up 5.5% from ₹4 crore in the same quarter last year.

Net profit fell 29.4% year-on-year to ₹0 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹0.53.

Operating profit stood at ₹0 crore — an operating margin (OPM) of 10.3%, compared with 6.7% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹9 crore with a net profit of ₹0 crore.

Shareholding pattern

As of Mar 2026, promoters held 64.21%, foreign institutional investors (FIIs) 0.32%, public shareholders 35.49% of Clinitech Laboratory Ltd.

Promoter holding rose from 62.42% to 64.21% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
N/A
Current Price ?
N/A
P/E ?
N/A
Industry P/E ?
N/A
P/B ?
N/A
P/S ?
N/A
P/FCF ?
N/A
Enterprise Value ?
N/A
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹9 Cr
OPM ?
10.5%
Profit after tax (TTM) ?
₹0 Cr
EPS (TTM) ?
₹1.84
ROCE ?
7.3%
ROE ?
4.5%
ROA ?
3.8%
Growth
Sales — latest qtr ?
₹4 Cr
PAT — latest qtr ?
₹0 Cr
YoY qtr sales growth ?
5.5%
YoY qtr profit growth ?
-29.4%
Sales growth (3y) ?
14%
Sales growth (5y) ?
16%
Profit growth (3y) ?
-12%
Profit growth (5y) ?
3%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.04
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
64.21%
Change in promoter holding ?
2.63%
Pledged percentage ?
N/A
Market
Return 3 months ?
N/A
Return 6 months ?
N/A

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 334454 +5.5% —
Operating Profit 011010 +60.7% —
Other Income 000000 -52.9% —
Interest 000000 +0.0% —
Depreciation 000000 +85.7% —
Profit Before Tax 000000 -13.8% —
Net Profit 000000 -29.4% —
EPS 0.471.790.960.741.310.53 -28.4% —
OPM % 9.2% 21.9% 13.7% 6.7% 10.6% 10.3% +53.7% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 1.501.682.282.28 +0.0%
Reserves 0.881.876.556.97 +6.4%
Borrowings 1.030.870.000.36 —
Other Liabilities 2.621.191.881.30 -30.9%
Total Liabilities 6.035.6110.7110.91 +1.9%
Fixed Assets 1.331.712.123.17 +49.5%
CWIP 0.560.941.010.00 -100.0%
Investments 2.020.070.070.08 +14.3%
Other Assets 2.122.897.517.66 +2.0%
Total Assets 6.035.6110.7110.91 +1.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1.25-1.28-0.88-0.90 -2.3%
Cash from Investing Activity -0.650.75-0.73-0.44 +39.7%
Cash from Financing Activity 0.090.453.980.33 -91.7%
Net Cash Flow 0.68-0.082.37-1.01 -142.6%
Free Cash Flow 0.97-2.49-1.73-1.45 +16.2%
CFO/OP 114%-115%-87%-70% +19.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 28.1734.2268.3071.23 +4.3%
Inventory Days 43.6892.91124.01118.42 -4.5%
Days Payable 124.79116.14147.4064.89 -56.0%
Cash Conversion Cycle -52.9510.9944.90124.76 +177.9%
Working Capital Days -33.3421.67114.87163.63 +42.4%
ROCE % 30.24%14.81%8.15%7.27% -10.8%

👥 Shareholding (latest 4 periods)

Metric Sep 2024Mar 2025Sep 2025Mar 2026 % Chg
Promoters 61.58%61.58%62.42%64.21% +2.9%
FIIs 0.32%0.32%0.32%0.32% +0.0%
Public 38.11%38.11%37.27%35.49% -4.8%
No. of Shareholders 346303303297 -2.0%

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.
❓ Frequently asked questions
What was Clinitech Laboratory Ltd's revenue in Q4 FY26?
Clinitech Laboratory Ltd reported revenue of ₹4 crore for the quarter ended March 2026 (Q4 FY26), up 5.5% from ₹4 crore in the same quarter last year.
What was Clinitech Laboratory Ltd's net profit in Q4 FY26?
Net profit fell 29.4% year-on-year to ₹0 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹0.53.
Who owns Clinitech Laboratory Ltd? (shareholding pattern)
As of Mar 2026, promoters held 64.21%, foreign institutional investors (FIIs) 0.32%, public shareholders 35.49% of Clinitech Laboratory Ltd.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI